Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 7;9(1):116.
doi: 10.1186/s40814-023-01354-7.

Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study

Collaborators, Affiliations

Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study

Rebecca L Gould et al. Pilot Feasibility Stud. .

Abstract

Background: Motor neuron disease (MND) is a fatal, progressive neurodegenerative disease that causes progressive weakening and wasting of limb, bulbar, thoracic and abdominal muscles. Clear evidence-based guidance on how psychological distress should be managed in people living with MND (plwMND) is lacking. Acceptance and Commitment Therapy (ACT) is a form of psychological therapy that may be particularly suitable for this population. However, to the authors' knowledge, no study to date has evaluated ACT for plwMND. Consequently, the primary aim of this uncontrolled feasibility study was to examine the feasibility and acceptability of ACT for improving the psychological health of plwMND.

Methods: PlwMND aged ≥ 18 years were recruited from 10 UK MND Care Centres/Clinics. Participants received up to 8 one-to-one ACT sessions, developed specifically for plwMND, plus usual care. Co-primary feasibility and acceptability outcomes were uptake (≥ 80% of the target sample [N = 28] recruited) and initial engagement with the intervention (≥ 70% completing ≥ 2 sessions). Secondary outcomes included measures of quality of life, anxiety, depression, disease-related functioning, health status and psychological flexibility in plwMND and quality of life and burden in caregivers. Outcomes were assessed at baseline and 6 months.

Results: Both a priori indicators of success were met: 29 plwMND (104%) were recruited and 76% (22/29) attended ≥ 2 sessions. Attrition at 6-months was higher than anticipated (8/29, 28%), but only two dropouts were due to lack of acceptability of the intervention. Acceptability was further supported by good satisfaction with therapy and session attendance. Data were possibly suggestive of small improvements in anxiety and psychological quality of life from baseline to 6 months in plwMND, despite a small but expected deterioration in disease-related functioning and health status.

Conclusions: There was good evidence of acceptability and feasibility. Limitations included the lack of a control group and small sample size, which complicate interpretation of findings. A fully powered RCT to evaluate the clinical and cost-effectiveness of ACT for plwMND is underway.

Trial registration: The study was pre-registered with the ISRCTN Registry (ISRCTN12655391).

Keywords: Acceptability; Acceptance and Commitment Therapy; Feasibility; Motor neuron disease; Psychological health.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Summary of recruitment and follow-up of participants in the study

References

    1. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617–628. doi: 10.1038/nrneurol.2013.203. - DOI - PubMed
    1. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5–6):310–323. doi: 10.3109/17482960802566824. - DOI - PMC - PubMed
    1. Turner MR. Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990–2002. J Neurol Neurosurg Psychiatry. 2003;74(7):995–997. doi: 10.1136/jnnp.74.7.995. - DOI - PMC - PubMed
    1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Neuromuscular Group, editor. Cochrane Database Syst Rev. 2012 [cited 2022 Apr 5]; Available from: https://doi.wiley.com/10.1002/14651858.CD001447.pub3. - DOI
    1. Weeks KR, Gould RL, Mcdermott C, Lynch J, Goldstein LH, Graham CD, et al. Needs and preferences for psychological interventions of people with motor neuron disease. Amyotroph Lateral Scler Front Degener. 2019;20(7–8):521–531. doi: 10.1080/21678421.2019.1621344. - DOI - PubMed

LinkOut - more resources